

## Joint Symposium 11

Neuroimaging Committee / European Association of Neuro-Oncology ([EANO](#))

Wednesday, June 29, 2022 / 08:00-09:30 / Channel 3

### Session Title

**Theranostic Approaches in Brain Tumours**

### Chairperson

**Antoine Verger** (Nancy, France)

### Programme

- 08:00 - 08:29 **Louisa von Baumgarten** (Munich, Germany): Current Drug Therapy Options for Brain Tumours - Is There a Need for Alternative Therapies?
- 08:29 - 08:58 **Philippe Garrigue** (Marseille, France): Basics for Brain Tumour Theranostics - Possible Targets and Requirements
- 08:58 - 09:27 **Tatjana Traub-Weidinger** (Vienna, Austria): New Theranostic Opportunities for Brain Tumours - Current Status and Challenges
- 09:27 - 09:30 Session Summary by Chairperson

### Educational Objectives

1. To learn about the status quo and current developments in brain tumour therapy
2. To get an overview on potential theranostic targets in brain tumours and to understand the requirements for a successful radioligand
3. To learn about the current status and challenges of theranostic applications in brain tumours

### Summary

The concept of theranostic approaches has emerged dramatically during the last years. At least since the great success of PSMA-directed imaging and treatment of patients with prostate cancer, it is increasingly recognized by clinical oncologists as valuable treatment option. The interest is particularly high for tumour entities with limited treatment options, such as primary and secondary brain tumours. New treatment options are urgently needed for oncological patients in the situation of brain metastases, for patients with advanced meningioma stages as well as for glioma patients, who still have a poor outcome without significant improvement despite decades of intense research.

The current session gives an overview on the current status and development of therapy options in brain tumours and outlines the need for new strategies. The session will discuss potential targets for radionuclide therapies, address general aspects of the evaluation of radionuclide therapy as well as the question how a promising target or radioligand with high potential to be an effective therapeutic can be successfully identified. Furthermore, an overview on theranostics that are currently applied or under investigation will be given.

### Key Words

Brain tumour therapy, theranostic, glioma, meningioma